1,3,8-Triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders
申请人:Ortho-McNeil Pharmaceutical, Inc.
公开号:US06777421B2
公开(公告)日:2004-08-17
The present invention is directed to novel 1,3,8-triazaspiro[4.5]decan-4-one derivatives of the general formula
wherein all variables are as defined herein, useful in the treatment of disorders and conditions mediated by the ORL-1 G-protein coupled receptor. More particularly, the compounds of the present invention are useful in the treatment of disorders and conditions such as anxiety, depression, substance abuse, neuropathic pain, acute pain, migraine, asthma, cough and for improved cognition.
本发明涉及新的1,3,8-三氮杂螺[4.5]癸酮衍生物,其一般式中所有变量如所定义,可用于治疗由ORL-1 G蛋白偶联受体介导的疾病和病症。更具体地说,本发明的化合物可用于治疗焦虑、抑郁、物质滥用、神经病性疼痛、急性疼痛、偏头痛、哮喘、咳嗽和改善认知功能的疾病和病症。